Aimmune Therapeutics Announces Third Quarter 2017 Financial Results and Planned Retirement of CEO by the End of 2018 by mparnell | Nov 6, 2017 | Portfolio News
Collegium Notified that the FDA Will Not Meet PDUFA Goal Date for sNDA for Xtampza® ER by mparnell | Nov 6, 2017 | Portfolio News
Jazz Pharmaceuticals Submits Vyxeos™ Marketing Authorization Application to European Medicines Agency for Treatment of Certain Types of High-Risk Acute Myeloid Leukemia by mparnell | Nov 3, 2017 | Portfolio News
Jazz Pharmaceuticals to Highlight Hematology Research at ASH 2017 Annual Meeting by mparnell | Nov 1, 2017 | Portfolio News